VIAVI Solutions slides as investors digest recent $500M equity offering and dilution overhang

Viavi Solutions Inc. (VIAV) is down 11.7% today. Here is some analysis on what might have caused this price movement.

Analysis: The most likely driver is continued selling pressure after VIAVI’s recently completed underwritten common-stock offering, which increased the share count and can create a near-term “dilution/overhang” effect. With the stock having rallied sharply earlier in 2026, today’s move also looks consistent with profit-taking and positioning after the financing and related debt paydown.

Details:

VIAVI priced an underwritten public offering of 11,111,111 shares at $45.00 per share, with gross proceeds expected to be about $500 million before fees and expenses.

The company stated it intended to use net proceeds primarily to repay the $450 million principal balance of its Term Loan B, with any excess for working capital and general corporate purposes.

The prospectus materials indicated the underwriters had an option to purchase additional shares, which can increase effective dilution and extend the market’s “deal digestion” period.

This could also be a technical pullback as investors reassess valuation after the post-earnings run-up, particularly if incremental supply from the offering met softer demand in the open market.

Sources:

SEC, Nasdaq, Investing.com

Disclaimer: This price movement analysis was generated with the help of AI. Please double-check the information provided for mistakes.

$VIAV Insider Trading Activity

$VIAV insiders have traded $VIAV stock on the open market 35 times in the past 6 months. Of those trades, 0 have been purchases and 35 have been sales.

Here’s a breakdown of recent trading of $VIAV stock by insiders over the last 6 months:

OLEG KHAYKIN (President & CEO) has made 0 purchases and 11 sales selling 549,950 shares for an estimated $18,547,680.
RICHARD BELLUZZO has made 0 purchases and 3 sales selling 79,943 shares for an estimated $3,493,105.
GARY W STALEY (SVP Global Sales NSE) has made 0 purchases and 7 sales selling 90,069 shares for an estimated $2,289,155.
KEVIN CHRISTOPHER SIEBERT (SVP Gen. Counsel & Secretary) has made 0 purchases and 4 sales selling 53,321 shares for an estimated $1,490,125.
LUKE M SCRIVANICH (SVP General Manager OSP) has made 0 purchases and 3 sales selling 24,594 shares for an estimated $936,356.
DONALD A COLVIN sold 25,000 shares for an estimated $730,750
DOUG GILSTRAP sold 10,000 shares for an estimated $550,000
PAUL MCNAB (EVP, Chief Mktg & Stgy Officer) has made 0 purchases and 3 sales selling 10,916 shares for an estimated $386,328.
RICHARD JOHN BURNS sold 3,384 shares for an estimated $63,483
EUGENIA CORRALES sold 3,384 shares for an estimated $63,483

To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.

$VIAV Hedge Fund Activity

We have seen 259 institutional investors add shares of $VIAV stock to their portfolio, and 223 decrease their positions in their most recent quarter.

Here are some of the largest recent moves:

PRICE T ROWE ASSOCIATES INC /MD/ added 8,681,201 shares (+576.6%) to their portfolio in Q1 2026, for an estimated $288,910,369
T. ROWE PRICE INVESTMENT MANAGEMENT, INC. removed 7,888,249 shares (-70.3%) from their portfolio in Q4 2025, for an estimated $140,568,597
ARROWSTREET CAPITAL, LIMITED PARTNERSHIP removed 5,897,957 shares (-88.4%) from their portfolio in Q1 2026, for an estimated $196,284,008
WELLINGTON MANAGEMENT GROUP LLP removed 5,556,301 shares (-50.5%) from their portfolio in Q1 2026, for an estimated $184,913,697
CAPITAL WORLD INVESTORS removed 4,050,091 shares (-25.9%) from their portfolio in Q1 2026, for an estimated $134,787,028
WHALE ROCK CAPITAL MANAGEMENT LLC added 3,473,152 shares (+inf%) to their portfolio in Q1 2026, for an estimated $115,586,498
FMR LLC added 3,282,361 shares (+548.3%) to their portfolio in Q1 2026, for an estimated $109,236,974

To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.

$VIAV Congressional Stock Trading

Members of Congress have traded $VIAV stock 2 times in the past 6 months. Of those trades, 0 have been purchases and 2 have been sales.

Here’s a breakdown of recent trading of $VIAV stock by members of Congress over the last 6 months:

REPRESENTATIVE GILBERT RAY CISNEROS, JR. has traded it 2 times. They made 0 purchases and 2 sales worth up to $30,000 on 03/27, 03/09.

To track congressional stock trading, check out Quiver Quantitative's congressional trading dashboard. You can access data on congressional stock trades through the Quiver Quantitative API Congress trades endpoint.

$VIAV Analyst Ratings

Wall Street analysts have issued reports on $VIAV in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.

Here are some recent analyst ratings:

Needham issued a "Buy" rating on 01/29/2026
Stifel issued a "Buy" rating on 12/17/2025

To track analyst ratings and price targets for $VIAV, check out Quiver Quantitative's $VIAV forecast page.

$VIAV Price Targets

Multiple analysts have issued price targets for $VIAV recently. We have seen 6 analysts offer price targets for $VIAV in the last 6 months, with a median target of $56.5.

Here are some recent targets:

Ryan Koontz from Needham set a target price of $68.0 on 04/30/2026
Mehdi Hosseini from Susquehanna set a target price of $65.0 on 04/30/2026
Andrew Spinola from UBS set a target price of $60.0 on 04/30/2026
Dave Kang from B. Riley Securities set a target price of $53.0 on 04/24/2026
Mike Genovese from Rosenblatt set a target price of $42.0 on 03/18/2026
Ruben Roy from Stifel set a target price of $24.0 on 01/29/2026

This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.